The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

All participants had obesity (BMI of ≥30 or ≥27 in Japan) and a diagnosis of moderate-to-severe obstructive sleep apnea (AHI ≥15 events per hour).

Obesity can lead to many complications, including increased risk for diabetes, heart disease, rheumatoid arthritis, depression, and high blood pressure. It can also lead to obstructive sleep apnea. 1 ...

Tirzepatide (Zepbound and Mounjaro), which is approved for chronic weight management and treatment of type 2 diabetes, has significant benefits for patients with moderate-to-severe obstructive sleep ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Obstructive sleep apnea is more common in men than women. Up to 34% of U.S. men have OSA compared to 17% of U.S. women, according to the American Academy of Family Physicians.

Nearly 53% of patients had comorbid obesity and obstructive sleep apnea, 73% reported three or more prior attempts at weight loss, 23% reported being current or past users of tirzepatide and/or ...

Obstructive sleep apnea is more common in men than women. Up to 34% of U.S. men have OSA compared to 17% of U.S. women, according to the American Academy of Family Physicians.

The new approval is for people with moderate to severe obstructive sleep apnea who are also living with obesity. Eli Lilly estimates that is about 15-20 million adults in the U.S.